The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

POSTER
Brilliance NT1: Study Design and Methods for Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating Alixorexton in Patients With Narcolepsy Type 1
Author(s):

Giuseppe Plazzi,1,2 Emmanuel Mignot,3 Richard K. Bogan,4 Ronald R. Grunstein,5,6 Gert Jan Lammers,7,8 David T. Plante,9 Rafael del Río Villegas,10,11 Hailu Chen,12 Bikram Kabir,12 Juan Chavez,12 Bhaskar Rege,12 Craig Hopkinson,12 Julie Himes,12 Yves Dauvilliers13
 

1IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; 2University of Modena and Reggio-Emilia, Modena, Italy; 3Stanford Center for Sleep Sciences and Medicine, Stanford University School of Medicine, Stanford, CA, USA; 4University of South Carolina School of Medicine, Columbia, SC, USA; 5Woolcock Institute of Medical Research, Macquarie University, Sydney, Australia; 6Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia; 7Leiden University Medical Center, Leiden, the Netherlands; 8Stichting Epilepsie Instellingen Nederland, Sleep‑Wake Centre, Heemstede, the Netherlands; 9University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA; 10Neurophysiology and Sleep Disorders Unit, Vithas Madrid Hospitals, Madrid, Spain; 11Departamento de Ciencias Médicas Clínicas, Universidad CEU San Pablo, CEU Universities, Madrid, Spain; 12Alkermes, Inc., Waltham, MA, USA; 13Sleep Unit, Gui de Chauliac Hospital, University of Montpellier, INSERM Institute for Neurosciences of Montpellier, Montpellier, France
 

Content available until 06/14/2029